(Q24809158)

English

Should an institution that has commercial rights in a new drug or device be allowed to evaluate the technology?

scientific article

In more languages

edit

Statements

instance of

scholarly article

0 references

title

Should an institution that has commercial rights in a new drug or device be allowed to evaluate the technology? (English)

0 references

author name string

Ross McKinney

series ordinal

1

0 references

David Korn

series ordinal

2

0 references

language of work or name

English

0 references

publication date

January 2005

0 references

published in

PLOS MEDICINE

0 references

volume

2

0 references

issue

1

0 references

page(s)

e9

0 references

copyright license

Creative Commons Attribution 4.0 International

start time

25 January 2005

1 reference

stated in

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

cites work

Death but one unintended consequence of gene-therapy trial.

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=545202

retrieved

30 May 2018

Gene therapy experiments put on "clinical hold"

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=545202

retrieved

30 May 2018

Academic relationships with industry: a new model for biomedical research.

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=545202

retrieved

28 November 2018

Protecting subjects, preserving trust, promoting progress II: principles and recommendations for oversight of an institution's financial interests in human subjects research

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/15696219

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Protecting subjects, preserving trust, promoting progress I: policy and guidelines for the oversight of individual financial interests in human subjects research

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/15696219

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Tube feeding bad for patients with dementia

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1371%2FJOURNAL.PMED.0020009

retrieved

7 January 2021

based on heuristic

inferred from DOI database lookup

Patients, but not doctors, like mediation for settling claims

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1371%2FJOURNAL.PMED.0020009

retrieved

7 January 2021

based on heuristic

inferred from DOI database lookup

Talks continue on UK juniors' pay.

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1371%2FJOURNAL.PMED.0020009

retrieved

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

DOI

10.1371/JOURNAL.PMED.0020009

0 references

PMC publication ID

545202

0 references

PubMed publication ID

15696219

0 references

ResearchGate publication ID

8036887

0 references

(Q24809158)

Should an institution that has commercial rights in a new drug or device be allowed to evaluate the technology?

Statements

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)